publication date: May. 11, 2018

Drugs and Targets FDA approves Darzalex for newly diagnosed multiple myeloma patients who are transplant ineligible

FDA has approved Darzalex (daratumumab) in combination with Velcade (bortezomib), a proteasome inhibitor; melphalan, an alkylating agent; and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Darzalex is sponsored by Janssen Pharmaceutical Companies, a unit of Johnson & Johnson.

Darzalex is the first monoclonal antibody approved for newly diagnosed patients with this disease. Clinical trial results showed Darzalex in combination with VMP reduced the risk of disease progression or death by 50 percent compared to treatment with VMP alone.

“This approval is significant as we now have the first antibody-based regimen for treating newly diagnosed multiple myeloma patients who are not eligible for a stem cell transplant,” said Andrzej Jakubowiak, director of the Multiple Myeloma Program at University of Chicago Medical Center, Chicago, Illinois and a Darzalex clinical study investigator. “In clinical studies, patients who received treatment with daratumumab experienced a lower risk of disease progression and higher rates of response.”

The FDA approval of Darzalex in combination with VMP is supported by data from the randomized, open-label, multicenter phase III ALCYONE (MMY3007) study, recently published in the New England Journal of Medicine.

The combination of … Continue reading FDA approves Darzalex for newly diagnosed multiple myeloma patients who are transplant ineligible

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.